Other companies have BTK in development and could partner or buy TGTX for 1202. Those companies realize1202 is the best in class PI3k inhibitor with a very safe profile. If TGTX combos can have similar efficacy, better safety, they can outcompete Abbie on price. Even if TGTX partners with a large pharma with a salesforce that will be beneficial.
Blue, you had impressed me with your post before, but this last one makes no sense from you. What immunotherapy companies have a lead candidate for CLL. What are the toxicities of immunotherapy candidates from JUNO and KITE etc, and at what cost. Would ABBV buy PCYC if Imbruvica would be obsolete in 3 years? Every stock is getting hammered, from Celg, gild, amgn that are very profitable. Why have more than 120 centers quickly signed up to participate in the Genuine trial? There is immediate need to treat these patients now.
Where did you get the price tag for 64K genius. Start by getting your facts straight, it might help your final conclusion. Then multiply by 8000 patients in US and 22,000 worldwide. They won't get 100% penetration but a significant portion. Disclosure...been long since the 20s, took some off the table. If it goes down, I'll buy back some. There are a lot of longs on the board that have done very well. The market and biotech are correcting, its nothing specific to vrtx.
Definitely possible. Biogen has no in-house drivers, their Alzheimer's drug has questions (Lilly's might be better and is ahead in development). Both are located in Boston and they probably could reduce overlap and workforces. Both are working on anti-lingo for MS. Definitely better leadership at Biogen then Vertex.
ABBVIE stretched itself to buy PCYC. JNJ also has rights to 50% of Imbruvica. They have deep pockets and should take out TGTX, Price will be much higher than 30. Plus, TGTX is essentially a future competitor to many companies with all its in-house combinations. GLTL
Rojo, this was all over the internet. Hope you picked up that it is years away. How expensive is it, is it ongoing inhalation. 3.5% is equivalent to what VRTX drugs provide NOW. What if VRTX triples and newer modalities go beyond 3.5%...Ireland was happy with 3.5% from this study., well that means they will pay for that now with Orkambi.
I expect Orkambi to be priced a little more than Kalydeco. Probably around $310K per year. Been a long since the 20s, and it has been a good ride. Expect big pharma to acquire. If it runs up with no acquirer, will take some off table.
Orchids, I am real, look me up. Long and strong!
Sentiment: Strong Buy